Akebia Therapeutics Inc (AKBA) - News Archive

In the intricate landscape of nephrology, the ongoing efforts to enhance treatment modalities for dialysis-dependent patients hold profound significance. A recent post hoc analysis of data concerning Vafseo (vadadustat)...

In a recent announcement, Akebia Therapeutics provided an important update regarding the development of Vafseo (darbepoetin alfa) for the treatment of anemia in non-dialysis patients. This statement follows the company’...

Akebia Therapeutics Expands Talent Pool with Inducement Stock Options Amid Recent Public OfferingCAMBRIDGE, Mass. Akebia Therapeutics Inc. (Nasdaq: AKBA), a biopharmaceutical company committed to improving the lives of...

Akebia Therapeutics Strengthens Team with Strategic Stock Option Inducements: A Look into Recent Grants and Company PotentialIn a strategic move that highlights Akebia Therapeutics Inc. s commitment to attracting top ta...

In a strategic move aimed at bolstering its talent pool, Akebia Therapeutics Inc. (Nasdaq: AKBA), a biopharmaceutical company devoted to improving the lives of individuals affected by kidney disease, has granted stock o...